Human Immunodeficiency Virus

Growth Hormone Treatment

Somatotropin (Human)

Mcgill University Health Center

Impact of Recombinant Human Growth Hormone on HIV Persistence

A Proof-of-concept Study to Assess the Effect of Recombinant Human Growth Hormone on the Size of the Replication-competent Viral Reservoir in HIV-infected Individuals on Suppressive Antiretroviral Therapy

Jean-Pierre Routy

McGill University Health Centre/Research Institute of the McGill University Health Centre

EMD Serono

intravenous infusion of furosemide (doses 125-250mg⁄ bid) from the first day after admission until 3 days before discharge Intervention: drug: furosemide ; other name: lasix

small volumes of hypertonic saline solutions (HSS) (150mL 1.4-4.6% NaCl), from the first day after admission until 3 days before discharge Intervention: Hypertonic saline solutions (1.4-4.6%NaCl) Intervention other name: not specified

no intervention Intervention: no drug only seriated paracentesis repeated paracentesis from the first day after admission until 3 days before discharge

Ascites

Cirrhosis

treatment with intravenous infusion of furosemide (doses 125-250mg⁄ bid) plus small volumes of HSS (150mL 1.4-4.6% NaCl), from the first day after admission until 3 days before discharge, with water restriction and a normal sodium diet.

intravenous furosemide

Intravenous small volumes of HSS (150mL 1.4-4.6% NaCl), plus treatment with intravenous infusion of furosemide (doses 125-250mg⁄ bid) from the first day after admission until 3 days before discharge, with water restriction and a normal sodium diet.

Hypertonic saline solutions

repeated paracentesis from the first day after admission until 3 days before discharge

Seriated paracentesis

Antonino Tuttolomondo

Internal Medicine Ward of Palermo University Hospital

Internal Medicine Ward, University of Palermo

Metabolic Effects of Furosemide +HSS in Refractory Ascites

Immune-inflammatory and Metabolic Effects of High Dose Furosemide Plus Hypertonic Saline Solution (HSS) Treatment in Cirrhotic Subjects With Refractory Ascite

difference between ANP serum levels at admission and ANP serum levels at discharge.

difference between BNP serum levels at admission and BNP serum levels at discharge.

difference between IL-1 beta serum levels at admission and IL-1 beta serum levels

difference between serum visfatin at admission and serum visfatin at discharge.

difference between serum leptin at admission and serum leptin at discharge.

difference between serum TNF-alfa at admission and serum TNF-alfa at discharge.

difference between serum IL-6 at admission and serum Il-6 at discharge.

viremia/edema

Impact of Recombinant Human Growth Hormone on HIV Persistence

Metabolic Effects of Furosemide +HSS in Refractory Ascites

La base de datos de hierbas medicinales más completa respaldada por la ciencia